StockIQpro
NASDAQ:PMVP

PMV Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

PMV Pharmaceuticals, Inc. reported net income of −$77.7M in fiscal 2025. Free cash flow was −$73.6M, and the diluted share count rose 1.9%.Summary generated from PMV Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 6, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−55.4%
Debt / equityn/a
Free cash flow−$73.6M
FCF marginn/a
Share count change+1.9%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−58−77−80−85−86
Net income−58−73−69−59−78
Free cash flow−48−72−57−52−74

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations